Travere therapeutics completes sale of bile acid product portfolio to mirum pharmaceuticals

• travere received $210 million at closing and is eligible for up to $235 million in potential sales-based milestone payments • mirum has acquired travere's rights and assets related to cholbam ® and chenodal ® • advances travere's strategy to deliver new treatment standards from its pipeline of innovative medicines for rare diseases and strengthens financial foundation • expands mirum's leadership in rare liver disease with two additional commercial products and a near-term phase 3 label expansion opportunity
TVTX Ratings Summary
TVTX Quant Ranking